Teva Pharma (TEVA) Reports Top-Line Results from GALA Phase III Trial for Glatiramer Acetate, Says Data Met Primary Endpoint
Go back to Teva Pharma (TEVA) Reports Top-Line Results from GALA Phase III Trial for Glatiramer Acetate, Says Data Met Primary Endpoint| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 36.58 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.58 | 52 Week High | $66.55 | |||
| Open | $36.58 | 52 Week Low | $37.82 | |||
| Day High | $36.58 | P/E | N/A | |||
| Day Low | $36.58 | EPS | $0.00 | |||
| Volume | 39,469 | |||||
